Welcome back to Plenary Session podcast. We have a great show in store for you today. I'm talking with Nina Sanford and Bill Hall about their new paper in the JCO. It's in comments and controversies. It's entitled, Elucidating the Benefit of Radiation Therapy in G.I. Cancers. Rethinking trial endpoints and patient selection. Nina, Bill, it's great to see you.

Nina, this is the first time on the show. Is that right?

I'm excited to be here.

And for Bill, you're a seasoned pro.

This is number three.

I am thrilled to be back.

Number three.

When you do it five times, we mail you the jacket.

I'm looking forward to it.

You get the green jacket in the mail.

Yeah.

Nina, tell us about this paper. So I read this paper. It's very interesting.

We're talking about GI radiotherapy.

We're talking about the endpoints we need.

And it was all based on this idea that in a bunch of recent clinical studies, overall survival

didn't deliver as the endpoint.

Why don't you talk about that?

What was the motivating force

behind you guys thinking about this? Yeah, so first of all, thank you again for having me.

Excited to be here. So we actually didn't intend to make this into a paper. So Bill and I are

working on a trial together in pancreas cancer. Actually, I think it was the one we talked about

like a long time ago. It's still in the works. And I was getting ready to present it to the Pancreous Task Force in July.

...